This study has developed a method to prepare diastereo‐ and regio‐selective indoline‐fused 2,5‐diketopiperazine scaffolds. The synthetic process involved an Ugi four‐component reaction in which readily available starting materials were used and a metal‐free intramolecular post‐Ugi tandem consecutive 5‐exo‐trig/6‐exo‐dig cyclization under basic conditions. The plausible mechanism and substrate structures were elucidated by single‐crystal X‐ray diffraction analysis and supported by density functional theory calculations.
A camphorsulfonic
acid-mediated one-pot tandem consecutive approach
was developed to synthesize functionalized indole and 2-quinolone
derivatives from the Ugi four-component reaction by switching solvents.
A reaction of the Ugi adduct in an aprotic solvent undergoes 5-exo-trig cyclization to form an indole ring. In a protic
solvent, however, the Ugi adduct undergoes an alkyne-carbonyl metathesis
reaction to form a 2-quinolone ring.
Background: Receptor tyrosine kinases (RTK) represent a class of high affinity cell surface receptors that play a critical role in the development and progression of several types of cancers. Among the receptor tyrosine kinases, c-Met mediates diverse cellular responses critical for tumor progression, growth, and survival. Alteration of the c-Met signalling cascade represents an attractive approach aimed at blocking invasion and metastasis of cancer cells. The objective of this study was to investigate the pharmacological and pharmacokinetic properties of RP1040, a novel small-molecule inhibitor of c-Met kinase.
Methods: c-Met Kinase activity of RP1040 was determined using using an HTScan® recombinant human Met Kinase Assay Kit (Cell Signaling Technology, Beverly, MA) with modifications. Viability assay (MTT) was conducted to determine the growth inhibitory effect of the compound on the high c-Met expressing sk-LMS-1 cell line. Metabolic stability of the compound was evaluated in microsomes obtained from mouse, rat, dog, monkey, and human. Pharmacokinetic behaviour of RP1040 in plasma after single dose oral administration or IV injection was determined in male Wistar rats.
Results: RP1040 demonstrated remarkable potency against the purified Met kinase by inhibiting enzyme activity at low nanomolar concentrations (IC50 = 1.3 nM). In addition, the compound caused a significant reduction in viability of sk-LMS-1 cells stimulated with 100 ng/ml HGF (IC50 = 0.03 nM). Pharmacokinetic studies indicated good oral absorption of RP1040 with plasma concentrations above 100 nM up to 24 h post administration. The compound had an elimination half-life of 8.95 hr with a clearance value of 4.21 ml/min/kg indicating a propensity to act as a long acting drug in this class. Further, RP1040 was metabolically stable across the species studied.
Conclusions: Our results demonstrate that RP1040 is a potent c-Met kinase inhibitor with a favourable pharmacokinetic profile and superior IC50 values compared to existing c-Met kinase inhibitors in development. RP1040 is currently being tested for in vitro and in vivo efficacy across various cancer cell lines and xenograft models besides selectivity against other receptor tyrosine kinases.
Citation Information: Mol Cancer Ther 2009;8(12 Suppl):C212.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.